|
|
|
| Key Health Policy Priorities Shaping The Second Half Of 2026 | Article | By Ana Amaris, ISPOR—The Professional Society for Health Economics and Outcomes Research | See late‑2025 policy actions, including international pricing agreements, new payment models, and global regulatory changes, while previewing key themes expected to shape 2026 health policy. |
|
|
| How Phase I Trial Ethics Are Changing For Sponsors | Article | BRANY | As early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs. |
|
|
|
|
| DGOF Readiness Package For Research Institutions | Brochure | Univo IRB | Our DGOF Readiness Package provides a coordinated set of templates that assist you in achieving compliance. It includes an institutional policy, an IRE charter, and a standard operating procedure. |
|
|
| Clinical Trial Regulations | Brochure | CHDR | This essential guide walks through mastering the complex landscape of clinical trial regulations, providing a clear, practical breakdown of regulatory timelines, legal obligations, and more. |
|
|
| Driving Safety And Compliance Seamlessly | Datasheet | IQVIA Safety & Regulatory Compliance | Whether it’s accelerating market entry with the “FSP Country in a Box” solution or maintaining global compliance through expert oversight, IQVIA empowers organizations with scalable, localized support. |
|
|
|
| Why Vendor Oversight Breaks Down At Handoffs | Guest Column | By Pawankumar Suresh | Is a vendor handoff really complete once the file is sent? Not quite. Sponsors still need context, ownership, and evidence to keep trials moving. |
|
|
|
|
|
|
|
|
|
|
|
| Connect With Clinical Leader: |
|
|
|